A retrospective analysis using monte carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit

Clinical Therapeutics

Volumn 27, Issue 6, 2005, Pages 762-772

  Mouton, Johan W ^a   Punt, Nieko ^b   Vinks, Alexander A ^c  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b Medimatics   (Netherlands)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Breakpoints; Ceftazidime; Monte Carlo simulation; PK PD; Probability of target attainment

Indexed keywords

CEFTAZIDIME;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DOSE REGIMEN; DRUG SENSITIVITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MONTE CARLO METHOD; PARAMETER; PHARMACODYNAMICS;

EID: 27744496551     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.06.013     Document Type: Article

References (42)

1. Ambrose PG, Bhavnani SM, Jones RN, Craig WA. Use of pharmacokinetics- pharmacodynamics and Monte-Carlo simulation as decision support for the reevaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 12-November 2, 2004; Washington, DC. Abstract A138.
2. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints and epidemiological cut-off Available at: www.eucast.org. Accessed January 15, 2005.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
4. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents. 2002;19:261-268.
5. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumonia. Diagn Microbiol Infect Dis. 2000; 38:151-157.
6. Mouton JW. Breakpoints: Current practice and future perspectives. Int J Antimicrob Agents. 2002;19:323-331.
7. Drusano GL, D'Argenio DZ, Preston SL, et al. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother. 2000;44:1655-1659.
8. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother. 2001;45: 13-22.
9. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med. 2001;111(Suppl 9A):13S-18S.
10. Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45: 3468-3473.
11. Mouton JW, Schmitt-Hoffmann A, Shapiro S, et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother. 2004:48:1713-1718.
12. Mouton JW, Kerrebijn KF. Antibacterial therapy in cystic fibrosis. Med Clin North Am. 1990;74:837-850.
13. Lipman J, Gomersall CD, Gin T, et al. Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J Antimicrob Chemother. 1999;43:309-311.
14. Joynt GM, Lipman J, Gomersall CD, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47:421-429.
15. Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121-128.
16. Mouton JW, Horrevorts AM, Mulder PG, et al. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother. 1990;34:2307-2311.
17. Vinks AA, Touw DJ, Heijerman HG, et al. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit. 1994;16:341-348.
18. Leary R, Jelliffe R, Schumitzky A, VanGuilder M. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceeding of the 14th IEEE Symposium on Computer-Based Medical Systems. Bethesda, Md: IEEE Computer Society; 2001:389-394.
19. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978;6: 165-175.
20. Town DJ, Vinks AA, Jacobs F, et al. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther Drug Monit. 1996;18:562-569.
21. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: Dosage strategies for meropenem. Clin Ther. 2004;26:1187-1198.
22. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy. 1991;9:169-210.
23. Paradis D, Vallee F, Allard S, et al. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992;36: 2085-2092.
24. Sommers DK, Walters L, Van Wyk M, et al. Pharmacokinetics of ceftazidime in male and female volunteers. Antimicrob Agents Chemother. 1983;23: 892-896.
25. Nicolau DP, Nightingale CH, Banevicius MA, et al. Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996;40:61-64.
26. el Touny M, el Guinaidy MA, Abd el Barry M, et al. Pharmacokinetics of ceftazidime in patients with liver cirrhosis and ascites. J Antimicrob Chemother. 1991;28:95-100.
27. Padoan R, Brienza A, Crossignani RM, et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1983;103:320-324.
28. Leeder JS, Spino M, Isles AF, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther. 1984;36:355-362.
29. Kercsmar CM, Stem RC, Reed MD, et al. Ceftazidime in cystic fibrosis: Pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983; 12(Suppl A):289-295.
30. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996;40:691-695.
31. Drusano GL, Joshi J, Forrest A, et al. Pharmacokinetics of Ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother. 1985;27:605-607.
32. Castagnola E, Ros L. Temporary interruption of ceftazidime continuous infusion without reduction of activity: A computer-assisted simulation. J Chemother. 2001;13:395-401.
33. Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother. 1997;40:269-273.
34. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg. 2000; 179:436-440.
35. Rondanelli R, Dionigi RV, Regazzi MB, et al. Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients, Int J Clin Pharmacol Ther Toxicol. 1986;24:457-459.
36. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing, Infect Dis Clin North Am. 2003;17:579-598.
37. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001; 45:2793-2797.
38. de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10: 185-194.
39. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of betalactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501.
40. van Lent-Evers NA, Mathot RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of amino-glycosides on clinical outcome: A cost-effectiveness analysis. Ther Drug Monit. 1999;21:63-73.
41. Jelliffe R. Goal-oriented, model-based drug regimens: Setting individualized goals for each patient. Ther Drug Manit. 2000;22:325-329.
42. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004;48:125-130.